Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Gastroenterology | Infections | Internal Medicine | Nursing | Journal

Back to Journal Articles

Hepatitis C Birth Cohort Screening is Cost-Effective

Last Updated: November 04, 2011.

 

Screening cost-effective to identify infected individuals born between 1945 and 1965

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Birth cohort screening can be a cost-effective strategy to identify individuals infected with hepatitis C virus, according to a study published online Nov. 4 in the Annals of Internal Medicine.

FRIDAY, Nov. 4 (HealthDay News) -- Birth cohort screening can be a cost-effective strategy to identify individuals infected with hepatitis C virus (HCV), according to a study published online Nov. 4 in the Annals of Internal Medicine.

David B. Rein, Ph.D., from the National Opinion Research Center at the University of Chicago in Atlanta, and colleagues examined whether birth cohort screening for HCV was cost-effective among adults born between 1945 and 1965. The participants of this birth cohort underwent one-time HCV antibody testing. Outcome measures included identifying, treating, and achieving sustained viral response in cases; liver disease and death from HCV; medical and productivity costs; quality-adjusted life years (QALY); and incremental cost-effectiveness ratio (ICER).

The investigators found that, compared to the current system, an additional 808,580 cases of chronic HCV were detected through birth cohort screening, with a screening cost of $2,874 per detected case. Based on an assumption that the screening was followed by pegylated interferon and ribavirin treatment, the QALYs increased by 348,800 due to the screening, and costs increased by $5.5 billion for an ICER of $15,700 per added QALY. However, based on an assumption that treated cases were given a direct acting antiviral, pegylated interferon, and ribavirin after screening, the QALYs increased by 532,200 due to the screening, and cost increased by $19.0 billion, for an ICER of $35,700 per added QALY. Sensitivity analysis showed that the birth cohort screening ICER was stable but most sensitive to the discount rate and the losses of QALY assigned to disease states.

"Birth cohort screening for HCV in primary care settings was highly cost-effective," the authors write.

Abstract
Full Text

Copyright © 2011 HealthDay. All rights reserved.


Previous: Adoption of English Diet Could Reduce U.K. Mortality Next: Varenicline Tied to Increased Risk of Suicidal Behavior

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.